SCHEMBL480126

SCHEMBL480126

COC(=O)c1ccc(CBr)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.59
KDM4E B2RXH2 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MAPT P10636 4/20 0.47
ALDH1A1 P00352 2/20 0.46
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA12 O43570 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 3/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
MEN1 O00255 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7419600 0.87 MAPK1 (0.56) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL30460282 0.85 MAPK1 (0.44) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL19876837 0.85 MAPK1 (0.57) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL204895 0.84 MAPK1 (0.61) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL29695095 0.84 MAPK1 (0.61) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL1441132 0.84 MAPK1 (0.61) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL1287501 0.83 CA12 (0.50) L3MBTL1MAPTALDH1A1CA1CA2
SCHEMBL1439028 0.83 MAPK1 (0.59) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL17298235 0.83 MAPK1 (0.59) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL198840 0.83 MAPK1 (0.59) MAPK1KDM4EL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823019-A Indole compound with effect of treating idiopathic pulmonary fibrosis as well as preparation method and application thereof 沈阳药科大学 2025-04-15 CN claimed
CN-113135907-A Compound for improving alpha-tubulin acetylation level and preparation method and application thereof 山东大学 2021-07-20 CN claimed
CN-107805241-B Imidacloprid hapten, complete antigen, preparation method and application 福建安欣睿捷生物科技有限公司 2020-05-26 CN claimed
CN-109020921-A A kind of histon deacetylase (HDAC) HDAC6 inhibitor and the preparation method and application thereof 山东大学 2018-12-18 CN claimed
CN-107805241-A A kind of imidacloprid haptens, comlete antigen and preparation method and application 福建安欣睿捷生物科技有限公司 2018-03-16 CN claimed
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics PROSETTA BIOSCIENCES INC (US) 2026-05-14 US disclosed
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 US disclosed
EP-4680602-A1 HETEROCYCLIC COMPOUNDS AS SELECTIVE HDAC6 INHIBITORS Miralinc Pharma, Inc. (US) 2026-01-21 EP disclosed
EP-3976604-B1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2026-01-21 EP disclosed
EP-4673444-A1 OXADIAZOLE DERIVATIVE COMPOUNDS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2026-01-07 EP disclosed
EP-4642461-A1 COMPOSITIONS FOR PREVENTING AND TREATING RENAL FAILURE (RF) Chong Kun Dang Pharmaceutical Corp. (KR) 2025-11-05 EP disclosed
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2025-11-04 US disclosed
WO-1999012933-A2 PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE GLAXO GROUP LIMITED (GB) 1999-03-18 WO disclosed
EP-0778821-A1 ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF ZENECA LIMITED (GB) 1997-06-18 EP disclosed
WO-1996006822-A1 ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF ZENECA LIMITED (GB) 1996-03-07 WO disclosed
US-5447949-A Vision defects or cardiovascular disorders SMITHKLINE BEECHAM CORPORATION (US) 1995-09-05 US disclosed
EP-0585383-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 1994-08-17 EP disclosed
US-5317101-A Antihyperalgesics IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-05-31 US disclosed
EP-0585383-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1994-03-09 EP disclosed
WO-1992020651-A2 N-(HETEROARYL)-IMIDAZOLYL-ALKENOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics NCOR1, HAVCR2, NR3C1 MAPK1 3571/4885KDM4E 4577/4885L3MBTL1 2268/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 MAPK1 1183/4885KDM4E 1970/4885L3MBTL1 1047/4885
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics MAVS, SARS1, ZC3HAV1 MAPK1 4224/4885KDM4E 4045/4885L3MBTL1 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.